Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates

被引：0
|
作者：
Liu, Ying Poi
Lubelski, Jacek
Ehlert, Erich
Gielen, Sander
Miranda, Paula
de Haan, Martin
Nijmeijer, Bart
Petry, Harald
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2058
引用
收藏
页数：2
相关论文
共 28 条
  • [1] Clearance of Vector DNA Following Systemic Administration of AAV5-hFIX or AAV5-hFIX Padua in Patients with Severe or Moderate-Severe Hemophilia B
    Sawyer, Eileen K.
    Gielen, Sander
    Twisk, Jaap
    Long, Alison
    Gut, Robert
    BLOOD, 2019, 134
  • [2] CLEARANCE OF VECTOR DNA FOLLOWING SYSTEMIC ADMINISTRATION OF AAV5-HFIX OR AAV5-HFIX PADUA IN PATIENTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B
    Sawyer, E. K.
    Gielen, S.
    Twisk, J.
    Long, A.
    Gut, R.
    HAEMOPHILIA, 2020, 26 : 72 - 73
  • [3] Clearance of Vector DNA from Bodily Fluids in Patients with Severe or Moderate-Severe Hemophilia B Following Systemic Administration of AAV5-hFIX and AAV5-hFIX Padua
    Sawyer, Eileen K.
    Gielen, Sander
    Twisk, Jaap
    Gut, Robert
    MOLECULAR THERAPY, 2020, 28 (04) : 559 - 560
  • [4] Expression of human FIX in mice after administration of AAV5-hFIX
    Spronck, Lisa
    van Logtenstein, Richard
    Donald, Liz
    Petry, Harald
    Grosios, Nadina
    Nijmeijer, Bart
    Salmon, Florence
    HUMAN GENE THERAPY, 2014, 25 (11) : A114 - A115
  • [5] Safety and Efficacy of an Adeno Associated Virus-Based Vector Carrying the Human Clotting Factor IX Gene (AAV5-hFIX) As Studied in Non-Human Primates
    Nijmeijer, Bart
    Petry, Harald
    Spronck, Lisa
    Van Der Kruijssen, Corina
    Petersen, Jorgen
    Salmon, Florence
    BLOOD, 2014, 124 (21)
  • [6] A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after Dosing
    Spronck, Lisa
    Logtenstein, Richard
    Haan, Martin
    Twisk, Jaap
    Sier-Ferreira, Valerie
    Deventer, Sander
    Heijink, Liesbeth
    MOLECULAR THERAPY, 2020, 28 (04) : 425 - 426
  • [7] Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs
    Spronck, Elisabeth A.
    Liu, Ying Poi
    Lubelski, Jacek
    Ehlert, Erich
    Gielen, Sander
    Montenegro-Miranda, Paula
    de Haan, Martin
    Nijmeijer, Bart
    Ferreira, Valerie
    Petry, Harald
    van Deventer, Sander J.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 15 : 221 - 231
  • [8] Therapeutic human Factor IX (hFIX) activity after single treatment with AMT-060 (AAV5-hFIX) or AMT-061 (AAV5-Padua hFIX) in Hemophilia B patients with pre-existing anti-AAV5 humoral immunity
    Majowicz, Anna
    Nijmeijer, Bart
    Lampen, Margit
    Gut, Robert
    Sawyer, Eileen
    Spronck, Lisa
    de Haan, Martin
    Petry, Harald
    van Deventer, Sander
    Meyer, Christian
    Tangelder, Marco
    Ferreira, Valerie
    HAEMOPHILIA, 2020, 26 : 20 - 20
  • [9] Threshold dose of factor IX expression in non-human primates following IV administration of AAV8 vectors
    Mizukami, Hiroaki
    Mimuro, Jun
    Tsukahara, Tomonori
    Urabe, Masashi
    Kume, Akihiro
    Ohmori, Tsukasa
    Madoiwa, Seiji
    Sakata, Yoichi
    Ozawa, Keiya
    HUMAN GENE THERAPY, 2012, 23 (10) : A77 - A78
  • [10] Unswerving Factor IX Expression in NAb-negative Macaques following IV Administration of AAV8 Vector
    Mizukami, H.
    Mimuro, J.
    Ishiwata, A.
    Yagi, H.
    Ohmori, T.
    Madoiwa, S.
    Tsukahara, T.
    Urabe, M.
    Kume, A.
    Sakata, Y.
    Ozawa, K.
    HUMAN GENE THERAPY, 2010, 21 (10) : 1367 - 1367
123